Until now, patients using the Cellnovo System with daily insulin dose requirements over 50 units were obliged to use more than one cartridge every 3 days. This was leading to higher utilization costs and potentially limiting the adoption of the system by patients with higher insulin needs. They will now be able to refill the cartridge within three days of use and benefit from the quality of life offered by a miniaturized system, without any additional costs.
Sophie Baratte, Chief Executive Officer of Cellnovo, commented:¬†‚ÄúEnabling patients to refill their insulin cartridges allows us to offer the Cellnovo System to 100% of people with type 1 diabetes, and to some of people with type 2 diabetes. All current Cellnovo System users will have immediate access to these cartridges. This will contribute to the continuing commercial growth of the Company.‚Äù